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Bone marrow transplantation (BMT) is the current therapy of choice for several malig-
nancies and severe autoimmune diseases. Graft versus host disease (GVHD) is the major
complication associated with BMT.T lymphocytes and other leukocytes migrate into target
organs during GVHD, become activated and mediate tissue damage. Chemokines are well
known inducers of leukocyte trafﬁcking and activation and contribute to the pathogenesis
of GVHD. Here, we review the major animal models used to study GVHD and the role of
chemokines in mediating tissue damage in these models. The role of these molecules in
promoting potential beneﬁcial effects of the graft, especially graft versus leukemia, is also
discussed. Finally, the various pharmacological strategies to block the chemokine system
or downstream signaling events in the context of GVHD are discussed.
Keywords: GVHD, chemokines, inflammation, therapy
INTRODUCTION
Allogeneic haematopoietic cell transplantation (HCT) is a trans-
plant between two genetically non-identical individuals (Ferrara
et al., 2009). It is an important therapeutic option to treat vari-
ous malignant and non-malignant diseases, including acute and
chronic leukemias, myelomas, lymphomas, aplastic anemias, solid
tumors, and severe immunodeﬁciency disorders (Goker et al.,
2001). The number of allogeneicHCTs performed annuallyworld-
wide is estimated to be more than 20,000 (Choi et al., 2010). After
allogeneic HCT, some patients present with remission of primary
disease. In some cases, patients may develop a common secondary
complication in which transplanted cells reject the host tissues,
named graft versus host disease (GVHD). GVHD accounts for
15–30% of deaths following allogeneic HCT and is a major cause
of morbidity in up to 50% of transplant recipients (Ferrara et al.,
2009).
Graft versus host disease manifests in two different forms, acute
(aGVHD) and chronic (cGVHD). Acute GVHD occurs within
100 days of allogeneic HCT and is a rapidly progressive syndrome
that is characterized by profound wasting, immunosuppression,
and tissue injury in a number of organs, including the intestine,
spleen, skin, liver, and lung (Howard and Woodruff, 1961; Lapp
et al., 1985; Cooke et al., 1998; Wysocki et al., 2005; Socié and
Blazar, 2009). In aGVHD, cytokines stimulate donor T cells to
recognize host antigens that are presented by antigen-presenting
cells (APCs). These T cells become activated and migrate to tar-
get organs where they generate effector responses against the
host (reviewed by Wysocki et al., 2005; Jaksch and Mattsson,
2005). Unlike aGVHD, cGVHD occurs usually 100 days after bone
marrow transplantation (BMT) and resembles an autoimmune
syndrome (Will and Wynn, 2006). In addition to the effects medi-
ated by T cells, cGVHD involves B-cell stimulation, autoantibody
production, and systemic ﬁbrosis (Schroeder and DiPersio, 2011).
Although donor T cells may mount an effector response against
the host cells, these cells also play a very important role in prevent-
ing the recurrence of the original malignant disease, especially
when the HCT is given as a therapy for leukemia. These types
of responses are referred to as graft versus leukemia (GVL; John-
son et al., 1996, 1999; Kolb, 2008). Thus, the inhibition of GVHD
without interfering with GVL is of major interest therapeutically.
The management of GVHD is an old problem but is still
unresolved. Standard therapy for GVHD includes high doses of
corticosteroids, but the success of this therapy is not great, as mor-
tality rates are more than 40% (Devetten and Vose, 2004; Ferrara
andReddy,2006; Ferrara et al., 2009;Choi et al., 2010). In addition,
patients that develop corticosteroid refractory GVHD have a high
risk of death due either to GVHD itself or to secondary infections
(Ferrara and Reddy, 2006). Although new therapies, including
monoclonal antibodies against the IL-2 receptor (daclizumab),
the TNF-α receptor (entanercept), or TNF-α (inﬂiximab), and
immunosuppressive drugs, such as mycophenolate mofetil, have
been proposed to treat GVHD, these therapies are still not satisfac-
tory (Choi et al., 2010). A better understanding of the mechanisms
involved in the pathogenesis of GVHD may yield novel therapeu-
tic targets. The present review discusses the role of chemokines
and their receptors during GVHD.
Chemokines are a family of small proteins (about 8–14 kDa)
that are classiﬁed into four major groups based on the num-
ber and spacing of conserved cysteines; the groups include the
CC group (CCL1–28), the CXC group (CXCL1–16), the C group
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(XCL1–2), and the CX3C group (CX3CL1; Murphy et al., 2000;
Murphy,2002).Chemokines exert their effects through interaction
with one or more members of a family of seven transmem-
brane domain-containing G-protein-coupled receptors (Zlotnik
and Yoshie, 2000; Rot and Von Andrian, 2004; Charo and Ran-
sohoff, 2006). There are currently 10 identiﬁed CC chemokine
receptors (CCR1–10), 6 CXC receptors (CXCR1–6), 1 C recep-
tor (XCR1), and 1 CX3C receptor (CX3CR1; Murphy et al.,
2000; Murphy, 2002; Kittan and Hildebrandt, 2010; Russo et al.,
2010). Chemokine expression can be enhanced by inﬂammatory
cytokines (Mackay, 2001), and chemokines have an important
role in recruiting cells of the innate and adaptive immune sys-
tem to sites of inﬂammation (Rollins, 1997; Moser et al., 2004).
In addition, chemokines have been suggested to be important
for leukocyte activation (Choi et al., 2007), angiogenesis (Addi-
son et al., 2000; Strieter et al., 2005), haematopoiesis (Broxmeyer,
2008), and the organization and function of secondary lymphoid
tissues (Cyster, 1999; Muller et al., 2003; Ohl et al., 2003).
Understanding of the molecular mechanism involved in con-
trolling expression of chemokine and their receptors in GVHD
may provide efﬁcient strategies to manage of disease. However,
little is known about such mechanisms. Most studies report that
the conditioning regime are a initial signal to trigger production
of cytokines (such as TNF-α, IFN-γ, IL-1, IL-2) and, consequently,
up regulation of chemokine receptors and their ligands (Krenger
et al., 1997; Jaksch and Mattsson, 2005; Wysocki et al., 2005;
Mapara et al., 2006; Bouazzaoui et al., 2009; Kittan and Hilde-
brandt, 2010). TNF-α and IFN-γ are produced during the initial
phase of GVHD within lymphoid tissues and may induce produc-
tion of chemokines in target organs by host cells (Schroeder and
DiPersio, 2011). IFN-γ is crucial for differentiation of CD4+ T cell
into Th1 cells which increase the expression of CCR9, CCR5, and
CXCR6u and their ligands in intestine and liver (Yi et al., 2009). IL-
2 is another important cytokine involved in T cell activation and
expansion (Jaksch and Mattsson, 2005) and inﬂuences produc-
tion of pro-inﬂammatory chemokines such asCCL2,CCL3,CCL4,
CCL5 (Jaksch and Mattsson, 2005;Wysocki et al., 2005; Choi et al.,
2007;Castor et al., 2010;Kittan andHildebrandt, 2010). Therefore,
the conditional regime and the cytokines associated with activa-
tion of T cells will provide the necessary stimuli for the production
of chemokines, which in turn will promote and orchestrate the
recruitment of immune cells during all phases of GVHD. Here,
we reviewed chemokines involved in the pathogenesis of GVHD
and discuss recent studies that have shown that interference in the
chemokine system using antibodies and compounds may decrease
the severity of GVHD while preserving the GVL response.
MECHANISMS AND MODELS OF GVHD
The pathogenesis of acute GVHD is currently understood as a
three-phase response. The ﬁrst phase is associated with the condi-
tioning regimen (irradiation/chemotherapy) that leads to damage
of host tissues, including the intestinal mucosa and liver (Ferrara,
1993; Hill et al., 1997; Jaksch and Mattsson, 2005; Mapara et al.,
2006). The second phase is characterized by activation and pro-
liferation of donor T cells. After transplantation, donor T cells
interact with host APCs, recognize host antigens, become acti-
vated, and differentiate into effector cells (Jaksch and Mattsson,
2005; Wysocki et al., 2005). The greater the disparity between
donor and recipient major histocompatibility complex (MHC),
the greater the T cell response will be (Socié and Blazar, 2009).
The interaction of T cells with APCs usually occurs in secondary
lymphoid organs, including the spleen and lymph nodes (Zhang
et al., 2005), but it can also occur in other peripheral lymphoid
tissues, such as Peyer’s patches (PP; Murai et al., 2003). In the third
phase of the acute GVHD response, activated T cells migrate to
target organs (intestine, liver, lung, and skin) and release cytolytic
molecules and inﬂammatory cytokines, such as IFN-γ and TNF-
α, and undergo Fas/Fas ligand interactions (Baker et al., 1996;
Braun et al., 1996; Cooke et al., 1998; Schmaltz et al., 2001; Jaksch
and Mattsson, 2005). Recruitment of other effector leukocytes,
including macrophages, follows T cell migration, and this process
is thought to be important for the perpetuation of inﬂammatory
responses and the destruction of target organs (Socié and Blazar,
2009; Castor et al., 2011; Schroeder and DiPersio, 2011).
Although the migration of T cells into secondary lymphoid
organs during GVHD has been well characterized (Wysocki et al.,
2005), the migration of leukocytes into parenchymal organs is
less well understood. The latter process depends on interactions
between selectins (Ley and Kansas, 2004; Luster et al., 2005; Carl-
son et al., 2010; Lu et al., 2010) and integrins (Hogg et al., 2002,
2003) and their ligands aswell as on chemokine–chemokine recep-
tor interactions (Wysocki et al., 2005; Castor et al., 2010; Kittan
and Hildebrandt, 2010). Animal models of GVHD have provided
important insights into the three characteristic phases of aGVHD.
ANIMAL MODELS OF GVHD
Although there are clear differences between human and experi-
mental GVHD, the latter models are useful for performing mecha-
nistic and kinetic studies and investigating changes in tissues.Most
of the knowledge of the role of the immune system in the patho-
genesis of experimental GVHD comes from experiments in mice
(Schleuning, 2000; Shlomchik, 2007; Welniak et al., 2007; Ferrara
et al., 2009; Schroeder and DiPersio, 2011).
The most relevant murine models of aGVHD (summarized in
Table 1) involve transplantation of splenocytes and/or bone mar-
row cells and can vary depending on the irradiation dose used
to ablate host immune cells. Models using total body irradiation
(TBI), which is also referred to as myeloablative conditioning,
require reconstitution of the immune system with the infusion
of myeloid precursor cells. Usually, a dose of 5–10 × 106 cells is
enough to repopulate the bone marrow compartment and ensure
the survival of mice (Choi et al., 2011). An insufﬁcient or inad-
equate reconstitution of bone marrow can result in death due to
severe immunosuppression. In the early days following transplan-
tation,mice that had been subjected toTBI usually have chimerism
in their peripheral blood (i.e., they have a mixed population of
donor and host cells). However, from day 7 after BMT, the donor
haematopoietic cells have completely replaced the host cells (Choi
et al., 2011). Partial irradiation or non-myeloablative conditioning
does not require total bone marrow reconstitution. After trans-
plantation, recipient mice demonstrate mixed chimerism, and the
majority of the cells come from the donor (Choi et al., 2011).
In models in which mice are transplanted with a mix of allo-
geneic bone marrow cells and splenocytes, the animals usually
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Table 1 | Mouse models of graft versus host disease.
Donor Recipient Irradiation
dose (cGy)
Mismatched for Cell type and dose References
C57/Bl6 (H2b) Balb/c (H2d) 700–800 MHCI, MHCII, miHAs Splenocytes: 10–30×106/BM: 5×106 Mapara et al. (2006),
Chakraverty et al. (2006)
Balb/c (H2d) C57/Bl6 (H2b) 900 MHCI, MHCII, miHAs Splenocytes: 10–30×106/BM: 5×106 Calcaterra et al. (2008)
C57/Bl6 (H2b) B6D2F1 – MHCI, MHCII, miHAs Splenocytes: 5×107 Murai et al. (2003)
C57/Bl6 (H2b) B6D2F1 (H2d/H2b) 1100 MHCI, MHCII, miHAs Splenocytes: 10–30×106/BM 5×106 Kregner et al. (2000), Hilde-
brandt et al. (2004a)
C57/Bl6 (H2b) B6D2F1 (H2d/H2b) 400 MHCI, MHCII, miHAs Splenocytes: 30×106 Castor et al. (2010, 2011)
C57/Bl6 (H2b) B6.C-H2bm1(bm1) H2b
background with
mutation at MHC I)
950 MHC I CD8+: 1.5–7.5×106/TCD BM: 4×106 Rolink and Gleichmann
(1983), Sprent et al. (1986),
Serody et al. (1999, 2000)
C57/Bl6 (H2b) B6.C-H2bm12 (bm12)
H2b background with
mutation at MHC II)
950 MHC II CD4+: 1–5×106/TCD BM: 4×106 Rolink and Gleichmann
(1983), Sprent et al. (1986),
Serody et al. (1999, 2000)
C57/Bl6 (H2b) Balb.B (H2b) 850–1000 miHAs T cells: 2×106/TCD BM: 5×106 Berger et al. (1994), Zhang
et al. (2005)
succumb to more severe disease than if they are only transplanted
with bone marrow cells (Schroeder and DiPersio, 2011). Spleno-
cytes represent a population of mature immune cells that are pre-
pared to react against antigens when stimulated, whereas the bone
marrow containsmany immature immune cells that are not able to
develop an appropriate response against antigens. Therefore, the
response against host antigens in recipient mice is decreased when
bone marrow cells rather than splenocytes are given (Schroeder
and DiPersio, 2011). There is also a model of GVHD in which
recipient mice are not irradiated. In this model, an infusion of
5× 107 allogeneic cells is necessary to induce GVHD, and the
disease is not lethal (Murai et al., 2003).
Another important consideration about the induction of
GVHD in mice is the genetic origin of the donor cells. An allo-
geneic transplant is a transplant between MHC mismatched mice,
such as C57/BL6 (H2b) and Balb/c (H2d), in which there are dis-
parities in MHCI, MHCII, and miHAs (Schroeder and DiPersio,
2011). The parental model of transplantation between C57/BL6
(H2b) and B6D2F1 (H2b/d) mice, which is a result of the crossing
of C57/BL6 (H2b)×DBA/2 (H2d) mice, also shows mismatches
in MHCI, MHCII, and miHAs (Asavaroengchai et al., 2007; Cas-
tor et al., 2010, 2011). Semiallogeneic transplantation represents
the transplantation between mice that are mismatched for MHCI,
such as C57/BL6 (H2b) and B6.C-H2bm1 (bm1) mice, or between
mice that are mismatched for MHCII, such as C57/BL6 (H2b)
and B6.C-H2bm12 (bm12) mice (Rolink and Gleichmann, 1983;
Sprent et al., 1986; Serody et al., 1999, 2000), or between mice that
are mismatched for miHAs, such as C57/BL6 (H2b) and Balb.b
(H2b) mice (Berger et al., 1994; Zhang et al., 2005).
Another important consideration for the induction of GVHD
is the dose and type of donor cells. The severity of disease is
dependent on the number of donor cells that are infused, and the
disease becomes more severe as the number of transferred cells
increases (Schroeder and DiPersio, 2011). Finally, it is possible to
inject different T cell subsets, such as CD4+, CD8+, and Treg cells,
and NK cells, either separately or together. This strategy may be
useful to dissect the differential role of these subsets during GVHD
(Schroeder and DiPersio, 2011).
CHEMOKINES IN GVHD AND POSSIBILITIES OF
THERAPEUTIC APPROACHES
Several studies have now described there is increased expression
of chemokines and chemokine receptors in GVHD (New et al.,
2002; Jaksch and Mattsson, 2005; Mapara et al., 2006; Bouazza-
oui et al., 2009; Castor et al., 2011). The proﬁle of chemokine
and chemokine receptor expression is different in different target
organs of GVHD. Table 2 and Figure 1 summarize the expres-
sion of chemokines and chemokine receptors in GVHD in various
target organs and during different temporal phases of the disease.
LYMPHOID ORGANS
Soon after transplantation, donor cells migrate to secondary lym-
phoid organs and to lymphoid tissues associated with the mucosa,
such as PP (New et al., 2002; Murai et al., 2003). CCR7, which is
expressed on dendritic cells and naïve and central memory T cells,
is responsible for the circulation of these cells between lymphoid
organs in response to CCL19 and CCL21 and is therefore critical
for the initiation of GVHD (Kittan and Hildebrandt, 2010). Three
days after transplantation,CXCR3 ligands (CXCL9–11) are upreg-
ulated in secondary lymphoid tissues, and this event is followed by
the upregulation of CCL2,CCL3,CCL4, and CCL5 (Wysocki et al.,
2005). Upregulation of these ligands promotes the accumulation
and activation of T cells in lymphoid tissue, but not in periph-
eral target organs, such as the liver and lung (Panoskaltsis-Mortari
et al., 2000; Serody et al., 2000; Wysocki et al., 2004). CCR5 and
CCR2 are also involved in the circulation of lymphocytes to lym-
phoid organs in GVHD. CCR5 expression in donor T cells plays a
critical role in their accumulation in lymphoid tissues after allo-
geneic transplantation (Murai et al., 2003; Wysocki et al., 2004).
In 2000, Serody et al. showed that eliminating the expression of a
CCR5 ligand, CCL3, from donor T cells resulted in reduced CD8+
accumulation in the spleen. In contrast, we have recently shown
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Table 2 | Chemokine and chemokine receptor expression in acute GVHD.
Chemokine Expression in
lymphoid tissues
(weeks after
transplant)
Expression in target organs
(weeks after transplant)
References
Spleen/lymph nodes Intestine Liver Lung Skin
CXCL1 – + (1–3, 6) + (1, 2) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010)
CXCL2 – – + (1) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010)
CXCL9 + (1) + (1–3, 6) + (1–3) + (1–3, 6) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Wysocki et al. (2005)
CXCL10 + (1) + (1) + (1–3) + (1–3, 6) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Wysocki et al. (2005)
CXCL11 + (1) + (1–3, 6) + (1–3, 6) + (1–3) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Wysocki et al. (2005)
CXCL16 + (3, 6) + (1, 2, 3) – Bouazzaoui et al. (2009)
CCL2 + (1) + (1–3) + (1–3) + (1, 2) + (1, 2) Kittan and Hildebrandt (2010), Wysocki et al. (2005),
Castor et al. (2011)
CCL3 + (1) + (1–3, 6) + (1–3, 6) + (1–3, 6) Bouazzaoui et al. (2009), Wysocki et al. (2005), Castor
et al. (2011), Serody et al. (1999)
CCL4 + (1) – + (1–3, 6) + (1–3, 6) Wysocki et al. (2005)
CCL5 + (1) + (1, 2, 3) + (1–3, 6) + (1–3, 6) + (1, 2) Bouazzaoui et al. (2009), Wysocki et al. (2005), Castor
et al. (2011), Choi et al. (2007)
CCL6 + (1, 2) Reiss et al. (2001)
CCL7 + (1, 2) Reiss et al. (2001)
CCL8 – – + (1–3, 6) + (1, 2) Bouazzaoui et al. (2009)
CCL9 + (1, 2) Kittan and Hildebrandt (2010)
CCL11 + (1, 2) Kittan and Hildebrandt (2010)
CCL12 + (1–3) + (1–3, 6) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010)
CCL17 + (2) Wysocki et al. (2005)
CCL19 + (1) + (1, 2) Kittan and Hildebrandt (2010),Yakoub-Agha et al. (2006)
CCL20 + (1, 2, 3) + (1, 2, 3) + (1, 2, 3) Varona et al. (2006)
CCL21 + (1) Sasaki et al. (2003)
CCL27 + (1) Reiss et al. (2001)
XCL1 + (1–3, 6) + (1–3) + (1–3, 6) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010)
CX3CL1 + (1, 2) Ueha et al. (2007)
CHEMOKINE RECEPTORS
CXCR2 – + (2, 3) – Bouazzaoui et al. (2009)
CXCR3 + (1) + (1, 2, 6) + (1) + (1–3) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Wysocki et al. (2005)
CXCR6 + (1–3, 6) + (1–3) + (1–3, 6) Bouazzaoui et al. (2009), Ueha et al. (2007)
CCR1 + (1–3, 6) + (1, 2, 3) + (1, 2) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Choi et al. (2007), Ueha et al. (2007)
CCR2 + (1) + (1, 2) + (2, 3) + (3) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Wysocki et al. (2005), Ueha et al. (2007), Terwey et al.
(2005)
CCR4 + (2) Reiss et al. (2001)
CCR5 + (1) + (1, 3, 6) + (1, 2, 3) + (2) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010),
Wysocki et al. (2005), Ueha et al. (2007), Murai et al.
(1999)
CCR6 + (1, 2, 3) Varona et al. (2006)
CCR10 (1, 2) Reiss et al. (2001)
XCR1 – + (2, 3) + (2, 3) + (1, 2) Bouazzaoui et al. (2009), Kittan and Hildebrandt (2010)
CX3CR1 + (1, 2) Ueha et al. (2007)
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FIGURE 1 | Overview of chemokine and chemokine receptor expression in the major organs targeted by GVHD. Shown are the major target organs that
are affected by GVHD, the intestine, liver, lung, and skin, and the major chemokines and chemokine receptors that are expressed during the course of the
disease.
that CCL3 in donor cells is not important for CD8+ and CD4+
accumulation in the spleen, but it is important for their accumu-
lation in the intestine (Castor et al., 2010). Additionally, others
studies have shown that CCR5 expression or CCL3 production by
T cells is not important for their accumulation in PP and spleen
(Panoskaltsis-Mortari et al., 2000; Welniak et al., 2004; Wysocki
et al., 2004). CCR2 expression did not affect the accumulation of
CD4+ cells in the spleen, but it increased their activation, changed
the disease proﬁle from chronic to acute GVHD and promoted the
death of GVHD mice (Rao et al., 2003).
TARGET ORGANS
CXC chemokine subfamily
After the accumulation and activation of donor cells in secondary
lymphoid organs, these cells migrate to target organs (Wysocki
et al., 2005). CXCR3 and its ligands, CXCL9–11, are expressed in
the target organs of GVHD (liver, intestine, lung, and skin) and
are associated with the migration and maintenance of CXCR3+
donor cells in these organs (Duffner et al., 2003; Mapara et al.,
2006; Bouazzaoui et al., 2009). Elimination of CXCR3 from donor
cells or neutralization of its ligands reduces disease in the above
organs (Flier et al., 2001; Wysocki et al., 2005; Piper et al., 2007;
Kittan and Hildebrandt, 2010). As a result of this, several patent
applications for CXCR3 antagonists have been made, but none
have yet been approved for clinical use to treat GVHD and other
diseases in which CXCR3 participates (Pease and Horuk, 2009).
Considering the high expression of CXCR3 ligands in target organs
of GVHD (Duffner et al., 2003; Mapara et al., 2006; Bouazza-
oui et al., 2009), another novel therapeutic strategy is the use of
CXCR3-transfected Treg cells, which function as modulators of
GVHD development (Hasegawa et al., 2008). In this study, chemo-
tactic signals for CXCR3 attracted regulatory cells to target tissues,
resulting in decreased GVHD severity (Hasegawa et al., 2008).
The role of CXCR4 in GVHD is not completely under-
stood, but CXCR4 is a chemokine receptor that interacts with
chemokine stromal-derived factor-1 (SDF-1/CXCL12) and regu-
lates haematopoietic stem and progenitor cell (HSPC) trafﬁcking
(Moll and Ransohoff, 2010). Disruption of this interaction either
through cleavage of SDF-1 andCXCR4 or downregulation of SDF-
1 expression results in the rapid egress of HSPCs from the bone
marrow (Broxmeyer et al., 2005; Semerad et al., 2005; Moll and
Ransohoff, 2010). Mobilization of HSPCs from the bone mar-
row to the peripheral blood has become the standard method to
collect allografts from healthy related donors for transplantation
into patients with haematologic malignancies (Greenbaum and
Link, 2011). This procedure is associated with more rapid engraft-
ment, shorter hospital stay, and in some circumstances, superior
overall survival in comparison to unmanipulated bone marrow
(Greenbaum and Link, 2011). AMD3100 (Plerixafor; Genzyme,
Cambridge,MA,USA) is a small bicyclam molecule that functions
as a reversible inhibitor of SDF-1 binding to CXCR4 (Proudfoot
et al., 2010). Studies in murine models, healthy human volun-
teers, and patients have demonstrated a dose-dependent increase
in HSPC mobilization within a few hours of AMD3100 adminis-
tration. Thus, AMD3100 is emerging as a new drug for the man-
agement of HSCT (Devine et al., 2008; Pusic and DiPersio, 2008).
No prophylactic effect of AMD3100 has been described in relation
to GVHD, but based on the prophylactic results obtained with
other agents, such as G-CSF, that mobilize HSPCs, this possibility
should be investigated.
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CXCR6 and CXCL16 are other CXC chemokines that are
increased in the liver and intestine in GVHD. However, the role
of these molecules in the pathophysiology of GVHD is not clear
(Bouazzaoui et al., 2009). Some studies have shown an increased
expression of CXCR6 onCD8+ T cells that contributed to the early
recruitment of these cells to the liver (Sato et al., 2005; Ueha et al.,
2007).
Elevated expression levels of CXCL1, CXCL2, and the CXCR2
receptor were also found in the liver, lung, and skin of mice
subjected to GVHD. However, the role of these chemokines and
chemokine receptor was not completely elucidated and should be
explored in future studies.
CC chemokine subfamily
Chemokines of the CC subfamily, especially CCL2, CCL3, CCL4,
and CCL5, have been described to be important for the migration
of donor cells to target organs during GVHD development.
Some studies have shown increased levels of CCL2 early on in
the liver (Ichiba et al., 2003) and intestine (Castor et al., 2011)
of mice subjected to GVHD, but the role of this chemokine is
not clear. Increased levels of CCL2 contribute to the migration
of donor monocytes and macrophages to the lung as shown by
studies in which neutralization of CCL2 or absence of CCR2 on
donor cells resulted in reduced inﬂammatory inﬁltrates in the lung
and consequently, minor lung injury (Hildebrandt et al., 2004b).
The CCL2 receptor, CCR2, has an important role in the activation
and migration of CD8+ T cells in the intestine and liver dur-
ing GVHD (Terwey et al., 2005). CCR2 is also involved in lung
damage (Hildebrandt et al., 2003, 2004b,c, 2005). Chemokines
produced by T cells, such as CCL3 and CCL5, and cytokines, such
as TNF-α, enhance the recruitment of CCR2+ macrophages to
the lung; macrophages produce more TNF-α and thus perpetuate
the inﬂammatory response (Serody et al., 2000; Hildebrandt et al.,
2003, 2004b,c, 2005).
Three days after transplantation, CCL3 levels are already high
in the intestine of mice subjected to GVHD after sublethal con-
ditioning. The initial production of CCL3 is mostly derived from
host cells, but its production then switches to transplanted cells.
Indeed, 10 days after transplantation, donor cells were the major
source of CCL3 in the target organs of mice subjected to GVHD
(Serody et al., 1999; Castor et al., 2010). In 2010, our group showed
the effect of a chemokine binding protein, evasin-1, in a model
of GVHD in mice. Evasin-1 bound with high afﬁnity to CCL3
(K d 0.16 nM) and prevented its association with CCR1 or CCR5
(Frauenschuh et al., 2007). Neutralization of CCL3 by evasin-
1 decreased GVHD mortality and damage to the intestine and
liver and reduced the inﬁltration of CD4+ and CD8+ cells and
macrophages in the intestine. There was also a reduction in CCL5
levels in the intestine after CCL3 neutralization, suggesting that
CCL3 may upregulate CCL5 in this organ (Castor et al., 2010). The
CCL5:CCR1 interaction also contributes to target organ injury, as
blockade of this interaction resulted in suppression of alloreactive
T cell activation, leading to decreased liver and intestinal injury
(Choi et al., 2007).
As suggested by clinical and experimental studies, CCR5 is a
critical receptor that is associated with GVHD development. After
stimulation by donor cell CCL3, CCL4, and CCL5, CCR5 promote
the recruitment of alloreactive T cells to the intestine, resulting in
the perpetuation of the inﬂammatory response in this organ and
increasedGVHDmortality (Wysocki et al., 2005;Choi et al., 2007).
Besides modulating mortality and the recruitment of donor T cells
to target organs in experimental GVHD (Murai et al., 2003),CCR5
appears to be important in controlling skin injury in humans with
GVHD by promoting the recruitment of T cells to this site (Palmer
et al., 2010). CCR5 is a major receptor that recruits lymphocytes to
the skin of humans with GVHD and contributes to the production
of TNF-α, IL-2, and IFN-γ, which participate in the pathogenesis
of human GVHD (Palmer et al., 2010). Studies have shown that
loss of CCR5 function by a 32-nucleotide deletion (CCR5Δ32) in
patients undergoing allogeneic BMT resulted in a decreased inci-
dence of GVHD (Bogunia-Kubik et al., 2006). Furthermore, the
presence of the CCR5Δ32 genotype in both recipient and donor
cells displayed the highest protection (Bogunia-Kubik et al., 2006).
Thus, CCR5 may be an interesting target in GVHD. Although
maraviroc, which is an inhibitor of CCR5, has been approved by
the FDA for clinical use, no study has validated its use in GVHD
management.
CCL25 demonstrates protective properties in GVHD. Interac-
tion of CCL25 with its receptor, CCR9, leads to the induction
of regulatory T cells and suppresses antigen-speciﬁc immune
responses that are associated with GVHD (Hadeiba et al., 2008).
On the other hand,CCR9has also been identiﬁed as a critical hom-
ing receptor for lymphocytes into inﬂamed intestine, a process that
contributed to the development of intestinal diseases, such as coli-
tis andCrohn’s disease (Saruta et al., 2007).Considering thatCCR9
contributes to intestinal inﬂammatory diseases, an orally bioac-
tive inhibitor of CCR9, CCX282, was developed. CCX282 is now
in Phase III of clinical trials (Pease and Horuk, 2009; Proudfoot
et al., 2010) and will be a promising approach for the treatment of
intestinal GVHD.
CCL20:CCR6 interactions also appear to be relevant in GVHD.
Interaction of CCL20 with its receptor, CCR6, induces the recruit-
ment of alloreactive CD4+ cells to the intestine, liver, and skin of
mice that had been subjected to allogeneic transplantation. Infu-
sion of CCR6-deﬁcient cells resulted in reduced tissue damage
and disease severity (Varona et al., 2006). Alloreactive T cells can
produce CCL20, which can interact with CCR6 expressed on the
surface of Langerhans cells. Langerhans cells are the major APC in
the skin and are involved in the pathogenesis of cutaneous GVHD
(Merad et al., 2002, 2004). Host Langerhans cells can persist for
several months in the skin and are responsible for the onset of skin
GVHD by interacting with donor T cells (Durakovic et al., 2006).
In addition, alloreactive T cell production of CCL20 may attract
donor Langerhans cells to the skin, leading to local presentation
of host antigens and injury to the skin (Merad et al., 2002, 2004).
Another mediator that has relevance to human cutaneous GVHD
is CCL27 and its receptor, CCR10. Levels of CCL27 and CCR10
were increased in the skin of patients with GVHD and were asso-
ciated with the migration of alloreactive T cells to this organ (Reiss
et al., 2001; Faaij et al., 2006). CCL20:CCR6 and CCL27:CCR10
have been shown to play an important role in GVHD in target
organs,mainly the skin.However, there have beenno studies inves-
tigating therapeutic strategies to control the release or action of
these molecules in GVHD.
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In the CC chemokine subfamily, other members have been
found tobe increased inGVHDtarget organs, such asCCL7,CCL8,
CCL9,CCL11,CCL12,CCL19,and their respective receptors; how-
ever, the exact role of these chemokines in the development of
GVHD is not understood.
XCL and CX3CL subfamily
XCL1 is a chemokine whose expression is frequently increased in
GVHD target organs, but its function has not yet been explored.
Bouazzaoui et al. (2009) showed increased levels of XCL1/XCR1
in the intestine, liver, lung, and skin during the course of GVHD.
However, no information is available on the role of these mole-
cules in GVHD development, which could be exciting for future
studies.
Fractalkine, or CX3CL1, is the unique member of the CX3CL
family and is also involved in GVHD. High levels of CX3CL1 were
detected in the intestine of mice that had been subjected toGVHD.
Increased levels of this chemokinewere associatedwith the recruit-
ment of CD8+ T cells to the intestine that contributed to intestinal
damage (Ueha et al., 2007). Treatment with an anti-CX3CL1 anti-
body reduced the number of CD8+ T cells in the intestine of mice,
resulting in improved survival and clinical disease (Ueha et al.,
2007).
Considering the important role of many chemokines in facili-
tating GVHD development,Grainger and Reckless (2003) demon-
strated an alternative way to control the action of chemokines in
GVHD. The group used oligopeptides, which acted as functional
chemokine inhibitors. One member of this group, NR58-3.14.3,
suppressed both in vivo and in vitro migration of leukocytes to
CCL2, CXCL8, CCL3, and CCL5 (Reckless et al., 2001). These
oligopeptides were successfully tested in mouse models of GVHD,
resulting in reduced clinical disease, decreased inﬂammatory inﬁl-
tration, and less damage to the liver and lung (Miklos et al.,
2009).
The data above suggest that chemokines and their receptors
represent promising molecules to be explored as therapeutic tar-
gets to modulate GVHD. Future research will reveal additional
details surrounding the efﬁciency of these therapeutic strategies
in the control of the inﬂammatory responses that are associated
with GVHD.
DOWNSTREAM SIGNALING OF CHEMOATTRACTANT
RECEPTORS AND GVHD
Signaling by chemokine receptors is mediated by heterotrimeric
G-proteins (Horuk andProudfoot,2009).Activationof G-proteins
leads to activation of protein and lipid kinases, including mitogen-
activated protein (MAP), Janus kinase-signal transducer and acti-
vator of transcription (JAK-STAT), and phosphatidyl inositol-3-
kinase (PI3K), which mediate actin cytoskeleton rearrangement,
changes in integrin afﬁnity and avidity, leukocyte migration and
proliferation, and cellular differentiation and apoptosis (Ribas
et al., 2007; Russo et al., 2010).
Recent studies have attempted to elucidate the role of molecules
downstream of chemokine receptor signaling and to establish a
functional hierarchy involved in the development of GVHD, rep-
resented in Figure 2 (Cetkovic-Cvrlje et al., 2001, 2002; Cetkovic-
Cvrlje and Uckun, 2004; Sun et al., 2004, 2005; Hill et al., 2010;
Park et al., 2010; Castor et al., 2011; Ma et al., 2011). Modulation
of these downstream signaling molecules is an alternative way to
interfere with the chemokine/chemokine receptor system.
Wehave recently evaluated the role of PI3Kγ in thedevelopment
of GVHD (Castor et al., 2011). PI3Kγ in donor cells was relevant
for the initial surge of chemokine production in the target organs
of mice subjected to GVHD. In addition to production of pro-
inﬂammatory mediators in target tissues, inﬁltration of CD4+,
CD8+, and CD11c+ cells was decreased with the absence of PI3Kγ
in donor cells, and pharmacological blockade of PI3Kγ was asso-
ciated with decreased rolling and adhesion of leukocytes to target
organs as assessed by intravital microscopy. These effects on cell
recruitment were translated as overall clinical improvement and
decreased lethality in the absence of PI3Kγ or its pharmacological
inhibition in donor cells (Castor et al., 2011).
Phosphorylation of ERK-1/2 and STAT-3 are involved in
important events during T cell (allo) activation in GVHD, and
interference with STAT-3 phosphorylation can inhibit T cell acti-
vation and proliferation in GVHD both in vitro and in vivo (Lu
et al., 2008). Additionally, expansion of CD4+ and CD8+ T cells
depends on the expression of phospho[p]-STAT-1 and p-STAT-3.
GVHD-speciﬁc STAT-3/STAT-1 activation preceded the activation
of nuclear factor-κB (NF-κB) and MAP kinases and was associated
with the subsequent expression of interferon regulatory factor-1
(IRF-1), suppressor of cytokine signaling 1 (SOCS-1) and IL-17
(Ma et al., 2011). STAT-1 expression in the spleen preceded its
expression in target organs and was correlated with the chemokine
storm in these organs. STAT-3 expression was similar to that of
STAT-1 and was observed early in secondary lymphoid organs
and later in target tissues. In the spleen, STAT-3 expression was
correlated with high levels of IL-6 and IL-10. The marked change
in the IL-6/IL-10 ratio during the development of GVHD sug-
gests that STAT-3 may act as a promoter of inﬂammation during
the early priming and induction phase of GVHD (high IL-6/IL-
10 ratio) but may mediate anti-inﬂammatory signals at later time
points (low IL-6/IL-10 ratio; Ma et al., 2011). By contrast, early
inhibition of NF-κB may reduce GVHD by affecting primarily
the haematopoietic compartment with inhibition of donor T cell
expansion or host APC maturation. However, delayed inhibition
of NF-κB may interfere with target tissue regeneration or pro-
motion of inﬂammation, leading to worsening of GVHD (Sun
et al., 2004, 2005). Interestingly, cytokine signaling through JAK-
STAT-3 in GVHD was regulated by SOCS-3 (Hill et al., 2010).
Transplantation of donor T cells into SOCS-3 deﬁcient mice led
to persistent phosphorylation of STAT-3, resulting in enhanced T
cell proliferation, greater Th1 and Th17 differentiation, and pro-
duction of IFN-γ and IL-17 (Hill et al., 2010). Thus, SOCS-3 has a
regulatory effect and is an attractive target for GVHD therapeutic
modulation; functional augmentation of SOCS-3 may preferen-
tially inhibit alloreactive T cell proliferation and differentiate cells
away from pathogenic Th17/Th1 pathways. Janus kinase signaling
occurs downstream of chemokine receptor signaling, and there
are molecules that inhibit this pathway. One such inhibitor, CP-
690550, was found to decrease mortality and reduce target organ
damage in mice subjected to GVHD by suppressing donor CD4+
T cell-mediated (IFN)-γ production and inhibition of Th1 dif-
ferentiation (Park et al., 2010). Speciﬁc inhibitors of Janus kinase
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FIGURE 2 | Depicts of downstream signaling of chemoattractant
receptors in GVHD. Signaling by chemokine receptors is mediated by
heterotrimeric G-proteins. Activation of G-proteins leads to activation of PI3K,
JAK, STAT, and MAPK. In GVHD, activation of PI3Kγ, JAK, STAT-1/3 leads to
pro-inﬂammatory events that crucial to development of GVHD. STAT-3/STAT-1
activation preceded the activation of NF-κB and MAP kinases with the
subsequent expression of IRF-1, SOCS-1, and IL-17. NF-κB has a dual role in
development of GVHD, depending of phase of it expression. STAT-3
phosphorylation acts as a promoter of GVHD inﬂammation and is regulated by
SOCS-3.
3 (JAK-3) have already been tested as a treatment for GVHD.
The use of the JAK-3 inhibitor,WHI-P131 [4-(4′-hydroxyphenyl)-
amino-6,7-dimethoxyquinazoline], showed improved mortality
rates and decreased liver and skin damage (Cetkovic-Cvrlje
et al., 2001; Uckun et al., 2002). Another JAK-3 inhibitor, 4-
(3′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-
3), improved mortality rates and ameliorated the clinical symp-
toms of GVHD (Cetkovic-Cvrlje et al., 2002). A speciﬁc Bruton’s
tyrosine kinase (BTK) inhibitor (LFM-A13), was also tested as
a treatment for GVHD; treated mice showed increased survival
rates and had less clinical GVHD. The combined treatment of
LFM-A13 with JANEX-3 was more effective than treatment with
LFM-A13 or JANEX-3 alone (Cetkovic-Cvrlje and Uckun, 2004).
Taken together, these results indicate that signaling molecules
downstream of chemokine signaling may be useful targets for
treating GVHD.
GRAFT VERSUS LEUKEMIA
In the context of the treatment of hematological malignances,
such as leukemia, engraftment of donor cells is important to
restore the immune system after ablative therapy (Kolb, 2008).
In addition to reconstructing the immune system, the engrafted
cells are thought to contribute to chemotherapy by inducing
an anti-tumor effect, an effect that is known as (GVL; Rezvani
and Barrett, 2008). Several therapies that decrease GVHD may
decrease GVL, which is an undesirable outcome of such therapies
(Rezvani and Barrett, 2008). Therefore, it is generally accepted
that, in the context of haematopoietic stem cell transplantation,
a therapy should decrease or prevent GVHD but ideally should
not modify the associated GVL (Kolb, 2008; Rezvani and Barrett,
2008).
Although the chemokine system represents a promising system
to target to develop new GVHD therapies, it is also important to
understand the role of chemokines inGVL response. Evaluation of
GVLhas not been themajor focus of studies involving chemokines
and GVHD. However, we have found a few studies showing that,
by interfering with the chemokine system, it is possible to decrease
GVHD without interfering with GVL.
Our group (Castor et al., 2010) and Choi et al. (2007) demon-
strated that, despite the important action of CCR1 and its ligands,
CCL3, and CCL5, in the GVHD response, neutralization of CCL3,
or the absence of CCR1 in donor cells did not interfere with GVL
(Castor et al., 2010; Choi et al., 2007). The capacity of T cells to
eliminate tumor cells remained unaltered upon neutralization of
CCL3 by evasin-1 in mice subjected to GVHD (Castor et al., 2010).
The absence of CCR1 in donor cells also maintained the GVL
response in mice subjected to GVHD (Choi et al., 2007). Ueha
et al. (2007) veriﬁed the GVL response in a study investigating the
role of fractalkine (CX3CL1) in GVHD. In this study,CX3CL1 was
important for GVHD development, but not for the GVL response,
and treatment with anti-CX3CL1 decreased GVHD without mod-
ifying GVL. The same result was observed when a downstream
chemokine receptor molecule, PI3Kγ, was absent in donor cells.
Transplantation of PI3Kγ-deﬁcient splenocytes reduced the ability
of these cells to react against the host, but not against the tumor
(Castor et al., 2011).
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The results described above indicate that the clinical use of
inhibitors of these molecules may decrease the GVHD reaction
but not interfere with GVL responses.
CONCLUDING REMARKS
The explicit participation of chemokines in the pathophysiology
of different diseases has initiated the development of pharmaco-
logical strategies that can interfere with the chemokine system.
Chemokines function by signaling through seven transmembrane
G-protein-coupled receptors, which are one of the most drug-
gable classes of receptors in the pharmaceutical industry (Horuk
and Proudfoot, 2009).
Since 1996, interest in targeting the chemokine system has been
growing, especially after demonstration of the participation of
CCR5 as a co-receptor of HIV infection (Liu et al., 1996; Sam-
son et al., 1996). After those studies, the pharmaceutical industry
began investing in the development of molecules that could inter-
fere with chemokine/chemokine receptor interaction. Examples
of such molecules include chemokine receptor antagonists (Hes-
selgesser et al., 1998; White et al., 1998; Horuk and Proudfoot,
2009; Garin and Proudfoot, 2011), modiﬁed chemokines that act
as antagonist molecules (Proudfoot et al., 1999, 2010), neutraliz-
ing antibodies to the chemokines or their receptors (Gonzalo et al.,
1998) and chemokine binding proteins (Alcami, 2003; Smith et al.,
2005; Frauenschuh et al., 2007; Déruaz et al., 2008; Russo et al.,
2010). In 2007, the FDAapprovedmaraviroc, an inhibitor of CCR5
for the prevention of HIV infection, which was the ﬁrst triumph
for a small-molecule drug acting on the chemokine system. A sec-
ond small-molecule drug, a CXCR4 antagonist for haematopoietic
stem cell mobilization, was approved by the FDA at the end of
2008. The results of a Phase III trial with a CCR9 inhibitor for
Crohn’s disease are also promising. The latter drug could rep-
resent the ﬁrst success for a chemokine receptor antagonist to
be used as an anti-inﬂammatory therapeutic. Development of
this small-molecule drug conﬁrms the importance of chemokine
receptors as a target class for anti-inﬂammatory and autoim-
mune diseases (Proudfoot et al., 2010; Garin and Proudfoot,
2011).
There are many difﬁculties in translating beneﬁcial results from
murine studies to humans, one of which is the many caveats
and differences between disease in experimental models and
humans. Humans undergoing BMT have a primary disease and
are subjected to immunosuppressive treatments before and during
the transplantation. The usual conditioning regimen in humans,
which consists of chemotherapy and radiation, is not always used.
The source of donor cells and genetic and immunological dispar-
ities are also different from most animal models. Infectious chal-
lenges are not usually performed in conjunctionwith experimental
induction of GVHD, but infections are commonly observed in
immunosuppressed patients. Human microbiota is markedly dif-
ferent from the microbiota of a mouse kept in a pathogen-free
facility, and bacterial translocation and sepsis are important causes
of death in GVHD patients. Finally, young mice are usually used
in experimental GVHD induction, but GVHD is generally more
common in older people. These differences should not hamper
development of drugs against GVHD but do not need to be taken
into consideration when moving drugs forward into clinical trials.
Fewer studies have been performed to validate the use of
inhibitors of the chemokine system in experimental GVHD. In this
context,Evasin-1 (CCL3-CBP),CXCR3antagonists, anti-CX3CL1,
inhibitor of CCR5 and CCR9 (CCX282), oligopeptides, such as
NR58-3143, and inhibitors of molecules involved in downstream
signaling of chemokine receptors (PI3Kγ, STAT-1 and 3, JAKs,
and SOCS-1 and 3) decrease GVHD in mice and may hence rep-
resent an interesting clinical approach in humans. However, to
the best of our knowledge, there are no studies conﬁrming the
effects of inhibitors of the chemokine system inGVHD in humans.
Many experimental studies have not clariﬁed the mechanism by
which abrogation of inﬂammatory responses occur after use of
therapies based on chemokine inhibition. Therefore, more mech-
anistic studies are needed to understand in greater detail the use
of these therapeutic molecules in experimental GVHD. As men-
tioned above, any therapy for GVHD should decreased clinical
disease but not interfere with GVL. In this respect, strategies based
on CCL3, CCL5, and CX3CL1 appear to be the most promising
approach based on the existing experimental systems.
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